Matthew Ronsheim
Corporate Officer/Principal bei ENTASIS THERAPEUTICS HOLDINGS INC.
Vermögen: 607 245 $ am 30.04.2024
Aktive Positionen von Matthew Ronsheim
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01.09.2020 | - |
Karriereverlauf von Matthew Ronsheim
Ehemalige bekannte Positionen von Matthew Ronsheim
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.06.2016 | 01.08.2019 |
| Corporate Officer/Principal | 01.06.2016 | 01.08.2019 |
Ausbildung von Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
Operativ
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Börse
- Insiders
- Matthew Ronsheim
- Erfahrung
